Results of a National French Survey on use of KELIM model for management of patients with advanced stage epithelial ovarian cancer (SFOG Campus)

IF 0.8 4区医学 Q4 ONCOLOGY

Bulletin Du Cancer Pub Date : 2025-07-11 DOI:10.1016/j.bulcan.2025.04.007

Diana Bello Roufai , Houssein El Hajj , Phuong Lien Tran , Pierre Descargues , Guillaume Babin , Sarah Betrian Lagarde , Benoît You , Elise Deluche

{"title":"Results of a National French Survey on use of KELIM model for management of patients with advanced stage epithelial ovarian cancer (SFOG Campus)","authors":"Diana Bello Roufai , Houssein El Hajj , Phuong Lien Tran , Pierre Descargues , Guillaume Babin , Sarah Betrian Lagarde , Benoît You , Elise Deluche","doi":"10.1016/j.bulcan.2025.04.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Ovarian cancer, predominantly epithelial, is the ninth most common and fifth most lethal cancer among women in France, with late diagnosis and poor prognosis despite curative treatments. The KELIM model, built according to Ca125 kinetics, given its proven predictive and prognostic characteristics, has been implemented online to aid therapeutic decision-making.</div></div><div><h3>Method</h3><div>This study assessed the use of the KELIM score among French gynecological oncology experts using a survey sent from 13 December 2023 to 30 January 2024, through Google forms to all member of French Society of Gynecological Oncology (SFOG), Young of French Society of Gynecological Oncology (SFOG campus) and National Investigators Group for Ovarian and Breast Cancer Studies in France (GINECO-ARCAGY).</div></div><div><h3>Results</h3><div>Fifty-two respondents, mainly gynecology and medical oncologists, revealed that 58% of them have used KELIM score, primarily in neoadjuvant settings. Participants considered that the KELIM score was mainly used to define the chemosensitivity (79%) and to identify patients who could then receive bevacizumab (82%). In the maintenance setting, the KELIM score was reported as quite frequently used (41%). It was inconsistently used to help the surgical procedure decision (37%).</div></div><div><h3>Conclusion</h3><div>The KELIM score predictive value for chemosensitivity, is acknowledged, especially for bevacizumab indications. However, its adoption into routine practice is dependent on the level of familiarity of practitioners. The findings suggest that while KELIM is seen as a potential useful tool for reinforcing therapeutic strategies, including choice of maintenance therapy or sequence of cytoreduction surgery, its broader adoption requires enhanced education and prospective validation.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1095-1102"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin Du Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0007455125002838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Ovarian cancer, predominantly epithelial, is the ninth most common and fifth most lethal cancer among women in France, with late diagnosis and poor prognosis despite curative treatments. The KELIM model, built according to Ca125 kinetics, given its proven predictive and prognostic characteristics, has been implemented online to aid therapeutic decision-making.

Method

This study assessed the use of the KELIM score among French gynecological oncology experts using a survey sent from 13 December 2023 to 30 January 2024, through Google forms to all member of French Society of Gynecological Oncology (SFOG), Young of French Society of Gynecological Oncology (SFOG campus) and National Investigators Group for Ovarian and Breast Cancer Studies in France (GINECO-ARCAGY).

Results

Fifty-two respondents, mainly gynecology and medical oncologists, revealed that 58% of them have used KELIM score, primarily in neoadjuvant settings. Participants considered that the KELIM score was mainly used to define the chemosensitivity (79%) and to identify patients who could then receive bevacizumab (82%). In the maintenance setting, the KELIM score was reported as quite frequently used (41%). It was inconsistently used to help the surgical procedure decision (37%).

Conclusion

The KELIM score predictive value for chemosensitivity, is acknowledged, especially for bevacizumab indications. However, its adoption into routine practice is dependent on the level of familiarity of practitioners. The findings suggest that while KELIM is seen as a potential useful tool for reinforcing therapeutic strategies, including choice of maintenance therapy or sequence of cytoreduction surgery, its broader adoption requires enhanced education and prospective validation.

查看原文本刊更多论文

一项关于使用KELIM模型管理晚期上皮性卵巢癌（SFOG Campus）患者的法国全国调查结果。

目的：卵巢癌，主要是上皮性癌症，是法国妇女中第九大最常见和第五大最致命的癌症，尽管有治愈性治疗，但诊断晚，预后差。根据Ca125动力学建立的KELIM模型，鉴于其已证实的预测和预后特征，已在网上实施，以帮助治疗决策。方法：本研究通过谷歌表格向法国妇科肿瘤学会（SFOG）、法国妇科肿瘤学会（SFOG校区）的所有成员、法国卵巢癌和乳腺癌研究国家调查小组（gino - arcgy）的所有成员发送调查问卷，评估了法国妇科肿瘤专家中KELIM评分的使用情况。结果：52名受访者，主要是妇科和内科肿瘤学家，透露58%的人使用KELIM评分，主要是在新辅助设置。参与者认为KELIM评分主要用于确定化疗敏感性（79%）和确定随后可以接受贝伐单抗治疗的患者（82%）。在维护设置中，据报道KELIM评分被频繁使用（41%）。它不一致地用于帮助外科手术决定（37%）。结论：KELIM评分对化疗敏感性的预测价值是公认的，特别是对贝伐单抗适应症。然而，将其纳入日常实践取决于从业者的熟悉程度。研究结果表明，虽然KELIM被视为加强治疗策略的潜在有用工具，包括选择维持治疗或细胞减少手术的顺序，但其更广泛的采用需要加强教育和前瞻性验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin Du Cancer 医学-肿瘤学

CiteScore

1.90

自引率

16.70%

发文量

224

审稿时长

37 days

期刊介绍： Without doubt, the ''Bulletin du Cancer'' is the French language publication of reference in the field of cancerology. Official organ of the French Society of Cancer, this journal covers all the information available, whether in the form of original articles or review articles, but also clinical cases and letters to the editor, including various disciplines as onco-hematology, solids tumors, medical oncology, pharmacology, epidemiology, biology as well as fundamental research in cancerology. The journal proposes a clinical and therapeutic approach of high scientific standard and regular updates in knowledge are thus made possible. Articles can be submitted in French or English.